Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Investigating the Human Metabolism of the Minor Cannabinoid Cannabichromene

Award Number: F31AT013157
ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 02/01/2025
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

Investigating the Human Metabolism of the Minor Cannabinoid Cannabichromene - PROPOSAL SUMMARY (ABSTRACT) Following federal legalization of hemp and cannabinoids in 2018, as defined by <0.3% Δ9-tetrahydrocannabinol (Δ9-THC), use of minor cannabinoids has grown exponentially. Minor cannabinoids are considered cannabis- derived cannabinoids that are not Δ9-THC or cannabidiol (CBD). Currently, the most popular, and in highest abundance in the cannabis plant include cannabinol, cannabigerol, and cannabichromene (CBC). Importantly, these compounds are available in highly purified and concentrated amounts. CBC in particular is gaining in popularity due to anecdotal claims of anti-inflammatory, anti-tumor, and anti-depressant properties. Due to its recent legalization, comprehensive scientific literature investigating these claims and fundamental pharmacokinetic characteristics are lacking, and it is the goal of this proposal to address this gap in knowledge. Knowing Δ9-THC and CBD metabolites remain biologically active, we will characterize the metabolism of CBC and determine subsequent activity of the metabolites. Our preliminary data suggests the major phase I oxidative metabolite of CBC is the result of a cytochrome P450 (CYP)-mediated epoxidation and subsequent intramolecular rearrangement into 2’-hydroxycannabicitran. The kinetics of this reaction are unknown and therefore the reactivity of CBC metabolism requires further investigation. These initial findings support the notion that CBC pharmacology is complex, but by dissecting metabolism, novel therapeutic modalities limiting toxicological impacts will be identified. The goal of this proposal is to define the metabolic profile of CBC and characterize the biologic activity of CBC and its major metabolites to reveal potential therapeutic or toxicological aspects of this minor cannabinoid. It is our working hypothesis that CBC is heavily metabolized into both phase I- and phase II-type metabolites. We further hypothesize that these metabolites are biologically active and have potential to contribute to metabolizing enzyme inhibition and/or physiological effects of CBC. Through the utilization of translationally relevant systems, namely immortalized human hepatocyte/cholangiocyte cocultures (HepaRG cells), we will identify the human metabolites of CBC in vitro (Aim 1). In Aim 2, we will phenotype metabolizing enzymes (recombinant human CYP450s and uridine 5'-diphospho-glucuronosyltransferase (UGTs)) responsible for the production of major metabolites identified from Aim 1. Further, we will determine if CBC can cause drug-drug interactions and hepatocellular toxicity. We will then characterize the activity of the metabolites in the endocannabidome in silico and through in vitro assays (Aim 3). Taken together, these studies will reveal novel CBC metabolites, determine risk for drug-drug interactions, provide a basis for CBC metabolite activity, and impact safety guidelines in the future.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $35,082 )
2026	2026	THE REGENTS OF THE UNIVERSITY OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Research and Training in Complementary and Integrative Health	000	2	3/24/2026	NON-COMPETING CONTINUATION	$35,082
														Subtotal = $35,082

Issue Date FY: 2025 ( Subtotal = $35,082 )
2025	2025	THE REGENTS OF THE UNIV. OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Research and Training in Complementary and Integrative Health	000	1	12/20/2024	NEW	$34,518
2025	2025	THE REGENTS OF THE UNIV. OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Research and Training in Complementary and Integrative Health	002	1	8/22/2025	NEW	$564
2025	2025	THE REGENTS OF THE UNIV. OF COLORADO	13001 E 17TH PL STE F428	AURORA	CO	80045	ADAMS	USA	Research and Training in Complementary and Integrative Health	001	1	12/20/2024	NEW	$0
														Subtotal = $35,082

Grand Total All Awards = $70,164

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Investigating the Human Metabolism of the Minor Cannabinoid Cannabichromene

Award Number: F31AT013157

ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 02/01/2025

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer